Perrigo Company plc Defined Benefit Plan, Interest Cost
Perrigo Company plc (PRGO) reported Defined Benefit Plan, Interest Cost of $3.60 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-05-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanInterestCost · last filed 2017-05-22
- Perrigo Company plc defined benefit plan, interest cost for fiscal 2016 was $3.60M.
- Perrigo Company plc defined benefit plan, interest cost for fiscal 2015 was $2.40M, a 71.43% increase from fiscal 2014.
- Perrigo Company plc defined benefit plan, interest cost for fiscal 2014 was $1.40M.
| Period end | Defined Benefit Plan, Interest Cost 6 month | Defined Benefit Plan, Interest Cost 12 month |
|---|---|---|
| 2016-12-31 | $3.60M 10-K · filed 2017-05-22 | |
| 2015-12-31 | $1.70M 10-K · filed 2017-05-22 | |
| 2015-06-27 | $2.40M 10-K · filed 2017-05-22 | |
| 2014-06-28 | $1.40M 10-K · filed 2014-08-14 | $1.40M 10-KT · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |